Biopharma organizations have more technology than ever before.
Discovery teams collaborate using modern scientific platforms.
Laboratories generate vast amounts of experimental data.
Regulatory teams leverage consultants, intelligence providers, and submission systems.
Yet many organizations continue to struggle with a fundamental question:
Are we actually ready for IND submission?
The challenge is not a lack of information.
The challenge is connecting regulatory expectations, available evidence, identified gaps, and submission readiness into a single operational view.
This article explores why IND readiness remains difficult and where existing tools often leave critical gaps.
Core Components of the Modern Biopharma Stack
Discovery Platforms
Discovery platforms help scientific teams manage research, collaboration, and early-stage development activities. These systems excel at supporting scientific workflows. However, they are not designed to assess regulatory readiness.
Laboratory Information Management Systems (LIMS)
LIMS platforms provide structured management of laboratory data and experimental records. They play a critical role in data integrity and laboratory operations. However, laboratory data alone does not answer readiness questions.
Regulatory Consultants
Consultants provide valuable expertise and strategic guidance. They help organizations interpret regulatory expectations and prepare for submissions. However, consultant assessments are often periodic rather than continuous.
Submission and RIM Platforms
Submission systems manage regulatory submissions, documentation workflows, and records of regulatory interactions. These systems become increasingly important as submission activities accelerate. However, they generally assume organizations already understand what evidence is required. ---
Introduction
"What Is the Missing Readiness Layer?"
Many organizations have tools for generating evidence.
Many organizations have tools for managing submissions.
The challenge lies in the space between them.
Organizations frequently struggle to answer questions such as:
- Which regulatory expectations apply to our program?
- What evidence currently exists?
- Which expectations remain unsupported?
- Which gaps represent the highest risk?
- How prepared are we for submission?
These questions define readiness.
Yet they often remain difficult to answer consistently.
Common Challenges in IND Readiness
Expectations Are Distributed
Regulatory expectations may originate from multiple sources. Examples include FDA guidance, ICH guidelines, CMC expectations, industry standards, and historical regulatory feedback. Teams must understand which expectations are relevant to their specific program.
Evidence Is Fragmented
Evidence often exists across scientific platforms, laboratory systems, shared drives, quality systems, and regulatory documentation repositories. As programs evolve, maintaining visibility becomes increasingly difficult.
Gaps Are Hard to Quantify
Organizations frequently identify issues during preparation activities. However, understanding the overall impact on readiness is often challenging.
Readiness Is Dynamic
Readiness changes continuously as new data becomes available, studies are completed, documentation evolves, and regulatory expectations change. Static spreadsheets rarely reflect current readiness status. ---
Moving Beyond Point-in-Time Assessments
Traditional readiness reviews often occur at specific milestones.
While valuable, these assessments provide only a snapshot in time.
Modern organizations increasingly seek continuous visibility into:
- Applicable expectations
- Available evidence
- Outstanding gaps
- Submission preparedness
This allows teams to identify issues earlier and make more informed decisions throughout development.
A Practical Readiness Framework
Identify Expectations
Define the regulatory expectations relevant to the program.
Map Evidence
Link existing evidence to those expectations.
Identify Gaps
Determine where evidence is incomplete, outdated, or missing.
Monitor Readiness
Track progress over time and maintain visibility into unresolved issues. Together, these activities create a more structured approach to readiness management. ---
Essential Elements of a Mature Readiness Program
Clear Expectation Management
Defining and tracking regulatory requirements from the start.
Evidence Traceability
Mapping every scientific record to its corresponding regulatory obligation.
Gap Visibility
Real-time identification of missing data or documentation.
Cross-functional Collaboration
Connecting scientific, quality, and regulatory teams in a shared view.
Continuous Readiness Monitoring
Moving from milestone-based reviews to a real-time readiness dashboard. ---
Related Resources
- IND Readiness Guide: Preparing for Successful Investigational New Drug Submissions
- CMC Documentation Readiness Framework
- Regulatory Gap Assessments in Biopharma
About Beacon
BeaconOS helps biopharma organizations connect regulatory expectations, available evidence, identified gaps, and readiness decisions.
Positioned between scientific systems and submission platforms, BeaconOS provides continuous visibility into IND readiness and supports more informed regulatory decision-making throughout development.